Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland
Journal Paper/Review - Jul 13, 2020
Coste A T, Kritikos A, Li J, Khanna N, Goldenberger D, Garzoni C, Zehnder C, Boggian Katia, Neofytos D, Riat A, Bachmann D, Sanglard D, Lamoth F, Fungal Infection Network of Switzerland (FUNGINOS)
Echinocandins represent the first-line therapy of candidemia. Echinocandin resistance among Candida spp. is mainly due to acquired FKS mutations. In this study, we report the emergence of FKS-mutant Candida albicans/glabrata in Switzerland and provide the microbiological and clinical characteristics of 9 candidemic episodes. All patients were previously exposed to echinocandins (median 26 days; range 15-77). Five patients received initial echinocandin therapy with persistent candidemia in 4 of them. Overall mortality was 33%.